Lessons from the RE-ALIGN trial  by Iung, Bernard & Vahanian, Alec
Archives of Cardiovascular Disease (2014) 107, 277—279
Available  online  at
ScienceDirect
www.sciencedirect.com
SCIENTIFIC EDITORIAL
Lessons  from  the  RE-ALIGN  trial
Les  enseignements  de  l’étude  RE-ALIGN
Bernard  Iung ∗,  Alec  Vahanian
Cardiology  Department,  Bichat  Hospital,  AP—HP,  Paris  Diderot  University,  46,  rue
Henri-Huchard,  75018  Paris,  France
Received  5  February  2014;  accepted  6  February  2014
Available  online  4  April  2014KEYWORDS
Anticoagulant
therapy;
Valvular  disease;
Mechanical  prosthesis
MOTS  CLÉS
Traitement
anticoagulant  ;
Valvulopathies  ;
Prothèses  mécaniques
Patients  operated  for  mechanical  heart  valve  replacement  have  a low  rate  of  reinter-
vention  but  suffer  valve-related  events  due  to  thromboembolism  and  bleeding  caused  by
anticoagulant  therapy.  New  oral  anticoagulants  (NOACs)  are  easier  to  use  than  vitamin  K
antagonists  and  offer  a  good  compromise  between  efﬁcacy  and  safety  in  large  trials  on
venous  thromboembolism  and  non-valvular  atrial  ﬁbrillation  [1—5].  NOACs  were  therefore
also  promising  in  patients  with  mechanical  heart  valves.  However,  the  presentation  of  the
results  of  the  Randomized,  Phase  II  Study  to  Evaluate  the  Safety  and  Pharmacokinetics
of  Oral  Dabigatran  Etexilate  in  Patients  after  Heart  Valve  Replacement  (RE-ALIGN)  at  the
annual  congress  of  the  European  Society  of  Cardiology  in  September  2013,  followed  by
their  publication,  was  disappointing  [6].
The  RE-ALIGN  trial  was  a  phase  II  trial  in  which  the  main  endpoint  was  to  validate  a
dose  algorithm  to  obtain  a  trough  level  of  dabigatran  >  50  ng/mL.  Thromboembolic  events
and  bleeding,  which  are  the  usual  clinical  endpoints  in  studies  on  anticoagulant  therapy
for  prosthetic  heart  valves,  were  secondary  endpoints.  The  majority  of  patients  (68%)  had
single  aortic  valve  prosthesis,  but  only  29%  were  classiﬁed  as  at  low  risk  for  thromboem-
bolism.  Patients  were  randomized  according  to  a  2:1  ratio  to  dabigatran  or  warfarin,  either
during  the  ﬁrst  week  following  valve  replacement,  or  at  least  3  months  after  surgery.
Dabigatran  doses  in  the  RE-ALIGN  trial  were  far  higher  than  in  atrial  ﬁbrillation  or  venous
thromboembolism.  The  starting  dose  was  between  150  and  300  mg  twice  daily  according
to  creatinine  clearance  and  was  readjusted  according  to  actual  dabigatran  plasma  level.
The  lowest  dose  in  the  RE-ALIGN  trial  corresponded  to  the  highest  dose  in  the  Randomized
Evaluation  of  Long-Term  Anticoagulation  Therapy  (RE-LY)  trial  [3]. It  was  used  in  only  15%
of  patients  as  a  starting  dose  and  11%  after  readjustment.  Thus,  89%  of  patients  in  the
RE-ALIGN  trial  received  a  higher  dose  of  dabigatran  than  in  other  indications.
Abbreviations: INR, international normalized ratio; NOAC, new oral anticoagulant drug; RE-ALIGN, Randomized, Phase II Study to Evaluate
the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement; RE-LY, Randomized Evaluation of
Long-Term Anticoagulation Therapy.
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cause  serious  harm  to  the  patient  [13].  Beyond  the  imme-78  
During  follow-up  of  the  168  patents  allocated  to  dabiga-
ran,  5%  suffered  strokes,  2%  transient  ischaemic  attacks,
%  myocardial  infarctions  and  3%  asymptomatic  prosthetic
hrombosis.  On  the  other  hand,  the  only  thromboembolic
vents  in  the  84  patients  treated  with  warfarin  were  tran-
ient  ischaemic  attacks,  with  a  rate  of  2%.  Major  bleeding
as  observed  in  4%  of  patients  in  the  dabigatran  group  and
%  in  the  warfarin  group.  The  trial  was  not  powered  on  the
asis  of  clinical  events  and  this  explains  why  the  differences
etween  allocated  treatment  groups  did  not  reach  statisti-
al  signiﬁcance.  Although  the  primary  endpoint  was  not  in
uestion,  these  ﬁndings  were  sufﬁcient  to  bring  about  the
remature  termination  of  the  trial  and  to  add  an  explicit
ontraindication  of  dabigatran  in  patients  with  prosthetic
eart  valves.
The  excess  of  severe  bleeding  in  the  dabigatran  group
as  mainly  related  to  postoperative  pericardial  bleeding.
his  may  have  been  favoured  by  a  too  early  introduction  of
abigatran  after  valve  replacement.  However,  there  is  no
xplanation  for  the  excess  of  stroke,  which  was  observed
hroughout  follow-up  and  not  clustered  to  the  early  post-
perative  period,  which  is  known  to  be  at  higher  risk  for
hromboembolism.  The  conjunction  of  excess  thromboem-
olism  and  bleeding  makes  it  unlikely  that  the  use  of  higher
oses  of  dabigatran  would  improve  the  risk-beneﬁt  ratio  of
nticoagulant  therapy.
The  results  of  the  RE-ALIGN  trial  provide  further  proof
hat  the  safety  and  efﬁcacy  of  new  drugs  cannot  be  extrap-
lated  from  trials  conducted  in  other  contexts.  The  fact
hat  the  risk-beneﬁt  ratio  of  dabigatran  was  lower  in  the
E-ALIGN  trial  may  be  due  to  particularities  of  thrombosis
n  mechanical  valve  prosthesis.  The  artiﬁcial  components
f  the  prosthesis  activate  the  contact  pathway  of  secondary
aemostasis.  In  addition,  ﬂow  velocity  is  higher  in  valve
rostheses,  in  particular  in  the  aortic  position,  than  in
enous  thrombosis  or  in  atrial  ﬁbrillation.  Vitamin  K  antag-
nists  inhibit  four  factors  of  secondary  haemostasis  and
ay  ensure  a  more  complete  blockade  of  the  contact  path-
ay  than  a  drug  acting  on  a  single  factor.  This  is  also
n  illustration  of  the  limitations  of  animal  models,  which
uggested  that  dabigatran  was  effective  in  preventing  pros-
hetic  thrombosis  in  mechanical  heart  valves.
Therefore,  patients  with  mechanical  prostheses  will  con-
inue  to  be  treated  for  for  the  foreseeable  future  with
arfarin.  All  efforts  that  have  been  made  to  reduce
omplications  of  vitamin  K  antagonists  should  therefore
e  pursued,  in  particular  management  using  anticoagulant
linics  and  INR  self-monitoring.  Unstable  international  nor-
alized  ratios  (INRs)  are  associated  with  a  higher  rate  of
omplications  and  with  an  increase  in  long-term  all-cause
ortality  in  patients  with  mechanical  heart  valve  prosthe-
es  [7].  Self-monitoring  of  INR  not  only  improves  the  quality
f  life  of  patients  under  vitamin  K  antagonists,  but  also
ecreases  the  risk  of  thromboembolism  and  bleeding,  as
hown  by  a  meta-analysis  of  randomized  trials  [8].
The  results  of  the  RE-ALIGN  trial  cannot  be  extrapolated
o  other  direct  anticoagulant  drugs,  in  particular  anti-Xa
rugs  such  as  rivaroxaban,  apixaban  and  edoxaban.  How-
ver,  no  speciﬁc  trials  seem  to  be  planned  for  the  use  of
ther  NOACs  in  patients  with  mechanical  heart  valve  pros-
hesis.
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It  can  be  expected  that  the  current  absence  of  indication
f  NOACs  for  mechanical  prosthesis  will  be  an  incentive  to
ontinue,  or  even  strengthen,  the  trend  towards  favouring
mplantations  of  bioprostheses  at  the  expense  of  mechanical
alves.  In  the  report  of  the  European  Association  for  Cardio-
horacic  Surgery,  the  percentage  of  mechanical  prostheses
mplanted  decreased  steadily  during  the  2000s  and  repre-
ented  only  one  in  four  aortic  valve  replacements  in  2006
o  2008  [9].  In  the  United  States  Society  of  Thoracic  Sur-
eons’  database,  the  percentage  of  mechanical  aortic  valve
eplacement  decreased  from  50%  in  1997  to  20%  in  2006
10].
At  the  present  time,  it  is  clear  that  any  NOAC  should  not
e  used  in  patients  with  a  mechanical  valve  prosthesis  [11].
he  situation  is  less  clear  with  bioprostheses.  Bioprosthe-
es  do  not  require  anticoagulant  therapy  by  themselves  and
his  is  their  main  advantage.  However,  certain  patients  with
ioprosthesis  may  require  long-term  anticoagulant  ther-
py  when  there  are  other  indications,  in  particular  atrial
brillation  [11].  This  is  of  particular  importance  given  the
ontemporary  epidemiology  of  heart  valve  disease,  which
s  characterized  by  a  marked  increase  in  prevalence  after
he  age  of  65—70  years  [12]. This  age  also  corresponds
o  an  increased  prevalence  of  atrial  ﬁbrillation  and  to  the
ge  after  which  bioprostheses  are  favoured.  In  these  cases,
hrombogenicity  is  due  to  atrial  ﬁbrillation  and  not  to  the
rosthesis.  However,  patients  with  bioprostheses  were  not
ncluded  in  any  trial  evaluating  NOACs  in  atrial  ﬁbrillation.
he  immediate  consequence  of  the  RE-ALIGN  trial  was  the
ecision  from  the  European  Medicines  Agency’s  Committee
or  Medicinal  Products  for  Human  to  add  the  following  con-
raindication:  ‘‘Pradaxa® is  now  contraindicated  in  patients
ith  prosthetic  heart  valves  requiring  anticoagulant  treat-
ent’’.  This  statement  is  not  restricted  to  mechanical
rostheses.  The  prescription  of  NOACs  is  an  off-label  use
t  present  and  should  be  discouraged  in  patients  with  bio-
rosthesis.  This  issue  highlights  the  need  for  speciﬁc  trials
esting  the  efﬁcacy  and  safety  of  NOACs  in  patients  with
ioprostheses  and  atrial  ﬁbrillation.
Finally,  the  ﬁndings  of  the  RE-ALIGN  trial  will  have  limited
onsequences  in  the  fast-moving  ﬁeld  of  oral  anticoagulant
herapy,  since  patients  with  mechanical  heart  valve  pros-
hesis  only  account  for  a  small  number  of  all  prescriptions  of
nticoagulant  therapy  compared  with  atrial  ﬁbrillation  and
enous  thrombosis.  The  drug  company  should  be  acknowl-
dged  to  have  taken  the  risk  of  testing  a  new  drug  in
his  speciﬁc  and  risky  indication.  Unfortunately,  random-
zed  trials  have  always  been  scarce  in  the  ﬁeld  of  heart
alve  prosthesis,  although  the  RE-ALIGN  trial  highlights  their
mportance.  We  should  not  reproduce  the  experience  of
ow-molecular  weight  heparins,  which  are  widely  used  in
atients  with  mechanical  prosthesis,  but  are  still  off-label
ecause  of  the  lack  of  appropriate  controlled  trials.  The
E-ALIGN  trial  is  a  timely  warning  against  inappropriate
xtrapolations  on  indications  for  NOACs  and  off-label  pre-
criptions.  Inappropriate  use  of  NOACs  has  already  been
eported  in  patients  with  mechanical  prosthesis  and  mayiate  disappointment  following  a  ‘‘negative’’  trial,  the
ndings  of  the  RE-ALIGN  trial  should  be  a  strong  incentive
o  perform  speciﬁc  randomized  trials  testing  the  safety  and
[[
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efﬁcacy  of  presently  available  and  ongoing  NOACs,  at  least
in  patients  with  atrial  ﬁbrillation  and  bioprosthesis  or  valve
repair.
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